VNRX · Volitionrx Ltd
Substantial doubt about the company's ability to continue as a going concern.
“The Company concluded that these plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
2 customers — 38% of receivables (At December 31, 2025)
“At December 31, 2025 the two largest customer balances represented over 38% of the total outstanding accounts receivable balance.”
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| FTE personnel in research and development division | 36 | three months ended June 30, 2026 filing | — |
| FTE personnel in sales and marketing division | 8 | three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VNRX
this stock
Volitionrx Ltd
|
$2.33M | — | +40.0% | — | 8.8% |
|
ABT
Abbott Laboratories
|
$179.20B | -18.2% | +5.7% | 33.3 | 0.8% |
|
MDT
Medtronic plc
|
$121.04B | -1.5% | +8.4% | 23.3 | 3.1% |
|
SYK
Stryker Corp
|
$114.28B | -13.4% | +11.2% | 30.9 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.02B | -52.2% | +12.5% | 18.4 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VNRX | -6.2% | -34.2% | -93.4% | -32.9% | -96.7% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -5.1% | -33.6% | -101.5% | -33.7% | -109.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.